Chemoablation with Intensive Intravesical Mitomycin C Treatment: A New Approach for Non–muscle-invasive Bladder Cancer
- 1 September 2019
- journal article
- research article
- Published by Elsevier in European Urology Oncology
- Vol. 2 (5) , 576-583
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Intravesical therapies for bladder cancer – indications and limitationsBJU International, 2012
- Intravesical gemcitabine therapy for non‐muscle invasive bladder cancer (NMIBC): a systematic reviewBJU International, 2012
- Bladder Tissue Pharmacokinetics of Intravesical Mitomycin C and Suramin in DogsThe AAPS Journal, 2010
- Intensive Intravesical Mitomycin C Therapy in Non-Muscle-Invasive Bladder Cancer: A Dose Intensity ApproachUrologia Internationalis, 2010
- The Effect of Repeat Transurethral Resection on Recurrence and Progression Rates in Patients With T1 Tumors of the Bladder Who Received Intravesical Mitomycin: A Prospective, Randomized Clinical TrialJournal of Urology, 2006
- Phase II Study to Investigate the Ablative Efficacy of Intravesical Administration of Gemcitabine in Intermediate-Risk Superficial Bladder Cancer (SBC)European Urology, 2004
- A randomized comparative dose‐ranging study of interferon‐α and mitomycin‐C as an internal control in primary or recurrent superficial transitional cell carcinoma of the bladderBJU International, 2002
- BLADDER CANCER CLINICAL GUIDELINES PANEL SUMMARY REPORT ON THE MANAGEMENT OF NONMUSCLE INVASIVE BLADDER CANCER (STAGES Ta, T1 AND TIS)Journal of Urology, 1999
- Phase II trials in Ta, T1 bladder cancer. The marker tumour conceptBritish Journal of Urology, 1996
- A Model of Bladder Tumor Xenografts in the Nude RatJournal of Urology, 1995